Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 lung disorders characterized by inflammation and fibrosis of the lung parenchyma. These conditions, often progressive and potentially fatal, pose significant diagnostic and therapeutic challenges to healthcare professionals.
The pathophysiology of ILDs is complex and multifactorial, involving genetic predisposition, environmental exposures, and aberrant wound healing responses. These factors lead to alveolar epithelial injury, recruitment of inflammatory cells, and deposition of extracellular matrix, resulting in lung fibrosis and architectural distortion.
Patients with ILDs typically present with progressive dyspnea and non-productive cough. High-resolution computed tomography (HRCT) is the gold standard for diagnosis, revealing characteristic patterns such as reticular abnormalities, honeycombing, and ground-glass opacities. Pulmonary function tests often show a restrictive pattern with reduced diffusion capacity.
Management of ILDs is complex and often necessitates a multidisciplinary approach. Corticosteroids and immunosuppressants form the cornerstone of treatment for many ILDs. However, for idiopathic pulmonary fibrosis, the most common ILD, antifibrotic agents such as pirfenidone and nintedanib have shown benefit. Lung transplantation may be considered in severe cases.
The prognosis of ILDs varies widely, with median survival times ranging from 3 to 10 years depending on the specific ILD subtype. Early recognition and appropriate management can significantly improve patient outcomes. As healthcare professionals, understanding the complexities of ILDs is crucial to provide optimal care for these patients.
Interstitial lung diseases are a diverse group of disorders with significant morbidity and mortality. A thorough understanding of their pathophysiology, clinical presentation, diagnostic strategies, and management options is essential for healthcare professionals to effectively care for patients with these challenging conditions.
1.
Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.
2.
Navigating breast cancer diagnosis, treatment, and survivorship in Ethiopia
3.
No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire
4.
Specialized imaging improves overall prostate cancer survival by identifying benefits of salvage radiotherapy
5.
Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma
1.
Ferroptosis as a Therapeutic Target in Cancer
2.
Subchorionic Hematoma: Causes, Symptoms, and Treatment
3.
Adaptive Cell Therapies for Solid Tumors
4.
Engineered Niches for Blood-Cell Regeneration: Current Concepts and Clinical Implications
5.
Unlocking the Potential of Hemin: A Novel Approach to Health and Wellbeing
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
5.
Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation